Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

NCT02015169 ↗

Phase 2 Completed 32 enrolled Samsung Medical Center

NaSingle-groupOpen-labelTreatment

Summary

We planned this study to investigate the efficacy and safety of XELOX (capecitabine and oxaliplatin) plus lapatinib treatment in HER2-positive gastric cancer patients with liver metastasis.

Timeline

Start: 2012-07-09
Primary completion: 2017-07-17
Completion: 2017-11-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapatinib	Small molecule	1250 mg	—

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Summary

Timeline

Drugs

Indications